Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS

Tim Spelman, Tomas Kalincik, Vilija Jokubaitis, Annie Zhang, Fabio Pellegrini, Heinz Wiendl, Shibeshih Belachew, Robert Hyde, Freek Verheul, Alessandra Lugaresi, Eva Havrdova, Dana Horakova, Pierre Grammond, Pierre Duquette, Alexandre Prat, Gerardo Iuliano, Murat Terzi, Guillermo Izquierdo, Raymond M. M. Hupperts, Cavit BozEugenio Pucci, Giorgio Giuliani, Patrizia Sola, Daniele L. A. Spitaleri, Jeannette Lechner-Scott, Roberto Bergamaschi, Francois Grand'Maison, Franco Granella, Ludwig Kappos, Maria Trojano, Helmut Butzkueven

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)102-115
JournalNeurology: Clinical Practice
Volume6
Issue number2
DOIs
Publication statusPublished - Apr 2016

Cite this

Spelman, T., Kalincik, T., Jokubaitis, V., Zhang, A., Pellegrini, F., Wiendl, H., Belachew, S., Hyde, R., Verheul, F., Lugaresi, A., Havrdova, E., Horakova, D., Grammond, P., Duquette, P., Prat, A., Iuliano, G., Terzi, M., Izquierdo, G., Hupperts, R. M. M., ... Butzkueven, H. (2016). Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 6(2), 102-115. https://doi.org/10.1212/CPJ.0000000000000227